Nature Biotech's Melanie Senior delved into expections for the 2023 biotech outlook in her piece "Pharma deal making: a bright spot amid the gloom Biopharma M&A is back and IPOs are possible, but most biotechs aren’t out of the woods." General Partner Dirk Kersten gave his perspective on what the industry has in store.
Click here to access the article online.